Bio Pharma Dive
FEBRUARY 6, 2022
For the first time in years, biotechs no longer have an easy path onto Wall Street, a market reversal that could change what the next generation of young drugmakers looks like.
World of DTC Marketing
FEBRUARY 7, 2022
Board members and senior executives are bailing out of Biogen but will there be enough life vests? What has/is happening at Biogen is a train wreck, and the only way to correct this disaster is to tear it down and rebuild the company from the top down. According to Endpoint News” We’ve seen Biogen’s CSO exit under pressure in recent weeks, and senior marketing execs leave in an exodus as the company recoiled from a fierce backlash against the FDA’s ultra controversial app
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NY Times
FEBRUARY 8, 2022
A crucial Johnson & Johnson plant has stopped making its Covid vaccine, though the company says it has millions of doses in inventory.
Scienmag
FEBRUARY 9, 2022
NEW YORK, February 9, 2022– Astrophysics is one of the most popular science fields, igniting the imaginations of many as they learn about it from television shows or news of space exploration. Like many other STEM fields, though, it lags in attracting students of color. Studies have shown the benefits of diversity in STEM fields, […].
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bio Pharma Dive
FEBRUARY 10, 2022
The agency criticized Eli Lilly for using a trial run in China to seek approval of an immunotherapy it licensed from Innovent Biologics. Outside advisers agreed in a decisive vote that could have repercussions for several other drugmakers.
World of DTC Marketing
FEBRUARY 8, 2022
According to the Lancet, a medical journal, the incidence of depression and anxiety has soared in the pandemic—by more than 25% globally in 2020. That, combined with more people using online services, has led to a boom in mental-health apps. But are they safe and effective? Now that big companies prioritize employees’ mental health, some apps work with them to help entire workforces.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
pharmaphorum
FEBRUARY 9, 2022
In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. According to a report by IQVIA last year, there were 3,500 oncology-focused therapeutic candidates in the pipeline, which represents a 75% increase on figures seen in 2015.
Bio Pharma Dive
FEBRUARY 8, 2022
In documents released Tuesday, FDA staff gave a cool review to an immunotherapy developed by Eli Lilly and Innovent Biologics. An advisory meeting this week to review it could have broader implications for cancer drug development in the U.S.
World of DTC Marketing
FEBRUARY 11, 2022
Pfizer has held a vaccine monopoly, blocking low-income countries from accessing its novel technology, while enriching shareholders at levels advocates for vaccine equity label “obscene.” The corporation is making as much as $1 million in profits every hour from vaccine sales, according to Oxfam, and its executives boast that revenues will expand exponentially in 2022. ( The Atlantic ).
Pharma Times
FEBRUARY 8, 2022
Greater urgency for kidney cancer treatments as 40% of UK patients wait 84 days for a diagnosis
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Scienmag
FEBRUARY 9, 2022
Baltimore, MD— The gut microbiome is an ecosystem of hundreds to thousands of microbial species living within the human body. These populations affect our health, fertility, and even our longevity. But how do they get there in the first place? Credit: By Navid Marvi, courtesy of the Carnegie Institution for Science. Baltimore, MD— The gut […].
Bio Pharma Dive
FEBRUARY 10, 2022
Safety concerns, including the recent death of a patient in an early study, led the FDA to place a hold on the therapy and Pfizer to redesign its Phase 3 trial.
World of DTC Marketing
FEBRUARY 10, 2022
( Washington Post ) Obesity turned out to be a major risk factor for covid hospitalization and death, especially non-elderly. According to the CDC, it is linked to impaired immune function and decreased lung capacity; it can make ventilation more difficult. Once again, obesity indicates that it’s killing us. The United States might well have gotten through the pandemic at far lower cost, economic and human, without the decades-long obesity epidemic that preceded it.
Pharma Times
FEBRUARY 11, 2022
Transaction advisory company heads to the big smoke as part of its expansion plans
BioPharma Reporter
FEBRUARY 8, 2022
Pfizer forecasts $32bn in revenue for COVID-19 vaccine Comirnaty, and $22bn for oral COVID-19 treatment Paxlovid, in 2022.
Bio Pharma Dive
FEBRUARY 8, 2022
The company estimated revenue from its COVID-19 vaccine and antiviral pill Paxlovid will total $54 billion this year. Curiously, its stock fell by more than 5%.
Outsourcing Pharma
FEBRUARY 9, 2022
The companyâs analysis of trials conducted around the world last year shows cancers took four of the top five positions, with COVID-19 in second place.
Pharma Times
FEBRUARY 10, 2022
Research demonstrates that people who live with peanut allergies face isolation and discrimination
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
BioPharma Reporter
FEBRUARY 7, 2022
Valneva and Pfizer have reported further positive Phase 2 data for their Lyme disease vaccine candidate, VLA15, with a Phase 3 trial set to start in Q3, 2022.
Bio Pharma Dive
FEBRUARY 11, 2022
The biotech's treatment did not improve vision in the Phase 2/3 trial, a significant setback that sent shares down by 75%.
pharmaphorum
FEBRUARY 11, 2022
Data from the first patients enrolled into Regenxbio’s trial of its gene therapy for rare inherited disease mucopolysaccharidosis type I (MPS I) – also known as Hurler syndrome – has shown the first signs of clinical activity. The results come from five patients enrolled in the biotech’s ingoing phase 1/2 study of RGX-111 – which uses an adeno-associated viral vector (AAV9) to deliver a gene coding for an enzyme that is deficient in MPS I patients – plus a single subject from an earl
Pharma Times
FEBRUARY 9, 2022
Sustainable lateral flow test kits developed in Birmingham reduce plastic and boost self-testing through ease of use
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Outsourcing Pharma
FEBRUARY 7, 2022
The HIV-focused pharma company announced the agency has approved Cabenuva for administration as few as six times a year for adults living with the virus.
Bio Pharma Dive
FEBRUARY 11, 2022
The FDA pushed back plans to expedite review of the shot in children under 5, seeking more data on a third dose. An advisory meeting scheduled for next week has been postponed as a result.
BioPharma Reporter
FEBRUARY 10, 2022
Having built up its mRNA expertise with its COVID-19 vaccine, Pfizer now sets out its strategy for the future. âGoing forward, we plan to continue to capitalize on the leadership we have built in both mRNA R&D and manufacturing.".
Pharma Times
FEBRUARY 8, 2022
NICE recommends appetite suppressing drug which can reduce a patient’s by more than 10%
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
FEBRUARY 9, 2022
The digitalisation that we all experience daily has affected the way we engage with stakeholders and patients. But how can we make Customer Engagement effective, and how can we leverage technologies like AI and Marketing Automation to their best potential? The key to success lies in implementing a digital health ecosystem , in order to support the shift from an organization-centric model to a customer-centric model by using digital platforms.
Bio Pharma Dive
FEBRUARY 11, 2022
Distribution of Lilly's earlier antibody treatments was halted as testing showed them ineffective against omicron. Bebtelovimab appears able to neutralize the variant, and was authorized by the FDA on Friday.
Outsourcing Pharma
FEBRUARY 8, 2022
The latest in the Diversity in Oncology series, taking place February 9, will discuss ways academia and community collaboration can narrow representation gaps.
Pharma Times
FEBRUARY 7, 2022
Institute for Cancer Research highlights missed opportunity for NICE to reform its cancer drug assessment processes
Expert insights. Personalized for you.
364 
Let's personalize your content